Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.

@article{Simonneau2012SelexipagAO,
  title={Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.},
  author={G{\'e}rald Simonneau and Adam Torbicki and Marius M Hoeper and Marion Delcroix and Krist{\'o}f Karl{\'o}cai and Nazzereno Gali{\`e} and Bruno Degano and Diana Bonderman and Marcin Kurzyna and Michela Efficace and Ruben Giorgino and Irene M Lang},
  journal={The European respiratory journal},
  year={2012},
  volume={40 4},
  pages={874-80}
}
In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension (PAH). 43 adult patients with symptomatic PAH (receiving stable endothelin receptor antagonist and/or a phosphodiesterase type-5 inhibitor therapy) were randomised three to one to receive either selexipag or placebo. Dosage was up-titrated in 200-μg increments from 200 μg twice… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
66 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Update on the development of oral prostacyclin analogs for the treatment of PAH

  • RJ White
  • Adv Pulmonary Hypertens
  • 2009

New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues

  • RJ Barst, LJ Rubin
  • Br J Pharmacol
  • 2007

prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues

  • RJ Barst, LJ Rubin, WA Long
  • Br J Pharmacol
  • 2007

Similar Papers

Loading similar papers…